SCHEMBL2178684

SCHEMBL2178684

Cc1ccc(C(=O)Nc2ccc(-c3ccc4c(c3)CN(C(C(=O)O)C(C)C)C4=O)cc2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SDCBP O00560 4/20 0.46
SDC2 P34741 4/20 0.46
LMNA P02545 2/20 0.43
TP53 P04637 1/20 0.43
NPC1 O15118 5/20 0.43
RAB9A P51151 5/20 0.43
DGAT1 O75907 1/20 0.43
MAPT P10636 3/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
KDM4E B2RXH2 1/20 0.42
MCL1 Q07820 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
ITGB3 P05106 1/20 0.40
ITGA2B P08514 1/20 0.40
ITGA2 P17301 1/20 0.40
ALDH1A1 P00352 1/20 0.40
NFKB1 P19838 1/20 0.40
NFKB2 Q00653 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2180871 1.00 SDCBP (0.46) SDCBPSDC2LMNATP53NPC1
SCHEMBL2179832 0.92 ITGB3 (0.46) SDCBPSDC2LMNATP53NPC1
SCHEMBL2179836 0.92 ITGB3 (0.46) SDCBPSDC2LMNATP53NPC1
SCHEMBL2180086 0.92 LMNA (0.49) SDCBPSDC2LMNATP53
SCHEMBL2180081 0.92 LMNA (0.49) SDCBPSDC2LMNATP53
SCHEMBL2177604 0.91 SDCBP (0.55) SDCBPSDC2LMNATP53ITGB3
SCHEMBL2180385 0.91 PTPN1 (0.48) SDCBPSDC2LMNATP53NPC1
SCHEMBL2177609 0.91 SDCBP (0.55) SDCBPSDC2LMNATP53ITGB3
SCHEMBL2182200 0.91 PTPN1 (0.48) SDCBPSDC2LMNATP53NPC1
SCHEMBL2177104 0.91 SDCBP (0.48) SDCBPSDC2LMNATP53DGAT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8748426-B2 Inhibitors of diacylglycerol acyl transferase Piramal Enterprises Limited (IN) 2014-06-10 US claimed
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Enterprises Limited (IN) 2012-11-15 US claimed
EP-2519500-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Healthcare Ltd. (IN) 2012-11-07 EP claimed
WO-2011080718-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-07-07 WO claimed
US-8748426-B2 Inhibitors of diacylglycerol acyl transferase Piramal Enterprises Limited (IN) 2014-06-10 US disclosed
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Enterprises Limited (IN) 2012-11-15 US disclosed
EP-2519500-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Healthcare Ltd. (IN) 2012-11-07 EP disclosed
WO-2011080718-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE DGAT1, DGAT2, LCAT SDCBP 2373/4885SDC2 3855/4885LMNA 2193/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.